130403-84-8Relevant articles and documents
BETA-LACTONE COMPOUNDS
-
Page/Page column 11, (2009/05/28)
The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and R1 comprises at least one moiety selected from a group consisting of an alkyl, an alkenyl, an aryl, a heterocycle, hydroxyl, ester, amido, aldehyde, and a halogen.
Discovery of a new chemical lead for a matrix metalloproteinase inhibitor
Ikura, Masahiro,Nakatani, Shingo,Yamamoto, Shingo,Habashita, Hiromu,Sugiura, Tsuneyuki,Takahashi, Kanji,Ogawa, Koji,Ohno, Hiroyuki,Nakai, Hisao,Toda, Masaaki
, p. 4241 - 4252 (2007/10/03)
A series of N-benzoyl γ-aminobutyric hydroxamic acids were synthesized and evaluated as matrix metalloproteinase inhibitors. First, we focused on chemical modification of the N-benzoyl residue. Introduction of electron-rich para-substituents was effective
Total synthesis and comparative analysis of orlistat, valilactone, and a transposed orlistat derivative: Inhibitors of fatty acid synthase
Ma, Gil,Zancanella, Manuel,Oyola, Yatsandra,Richardson, Robyn D.,Smith, Jeffrey W.,Romo, Daniel
, p. 4497 - 4500 (2007/10/03)
Concise syntheses of orlistat (Xenical), a two-carbon transposed orlistat derivative, and valilactone are described that employ the tandem Mukaiyama aldol-lactonization (TMAL) process as a key step. This process allows facile modification of the α-side chain. Versatile strategies for modifying the δ-side chain are described, involving cuprate addition and olefin metathesis. Comparative antagonistic activity of these derivatives toward a recombinant form of the thioesterase domain of fatty acid synthase is reported along with comparative activity-based profiling.
